carfilzomib
Showing 1 - 25 of 154
Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Detroit, Michigan
- +1 more
Jan 27, 2023
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
- Elranatamab
- Carfilzomib
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Chicago, IllinoisUniversity of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023
Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
San Francisco, California
- +3 more
Dec 24, 2022
Waldenstrom Macroglobulinemia Trial in Hackensack (Carfilzomib, Rituximab, Dexamethasone)
Completed
- Waldenstrom Macroglobulinemia
- Carfilzomib
- +2 more
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Mar 18, 2022
Carfilzomib in Patients With Multiple Myeloma
Recruiting
- Multiple Myeloma
- Carfilzomib
-
Odense, DenmarkOdense University Hospital
Dec 20, 2022
Kyprolis® in Combination With Revlimid® and Dexamethasone or
Recruiting
- Multiple Myeloma in Relapse
- Carfilzomib
-
Frankfurt, GermanyCentrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022
Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)
Recruiting
- Multiple Myeloma
- Dexamethasone
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)
Active, not recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Jan 9, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 14, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyFondazione EMN Italy Onlus
Mar 24, 2022
Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)
Active, not recruiting
- Multiple Myeloma
- carfilzomib
- +3 more
-
New York, New YorkWeill Cornell Medical College
Apr 10, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyFondazione EMN Italy Onlus
Mar 24, 2022
Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022
Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)
Completed
- Hematologic Malignancies
- +2 more
- Carfilzomib
- Tacrolimus
-
Ann Arbor, MichiganUniversity of Michigan Hospital
Dec 3, 2021
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,
Active, not recruiting
- Stage I Multiple Myeloma
- +2 more
- dexamethasone
- +4 more
-
Chicago, Illinois
- +4 more
Sep 3, 2022
Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Oct 5, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Aug 8, 2022
Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)
Recruiting
- Multiple Myeloma
- Selinexor 60 MG
- +6 more
-
Washington, District of Columbia
- +1 more
Feb 3, 2022